SMALL AND MID-CAP BIOTECHNOLOGY: MATTHEW OSBORNE - C.E.UNTERBERG, TOWBIN - The Wall Street Transcript

The Wall Street Transcript - In-Depth Interviews for Investors

Healthcare >> Analyst Interviews >> July 11, 2005

TWST: Would you begin with an overview of what you are covering?

Mr. Osborne: I follow small to mid-cap biotechnology companies covering

multiple therapeutic areas including cancer, endocrine

Join for free to read a longer excerpt or purchase this article